Aktion

Recombinant Human NRP1 Protein(His Tag)

Recombinant Human NRP1 Protein(His Tag)
Artikelnummer
ELSPDMH100255-500
Verpackungseinheit
500μg
Hersteller
Elabscience Biotechnology

Verfügbarkeit: wird geladen...
Preis wird geladen...

Special promotion: Enjoy a 10% discount on Elabscience recombinant proteins through September 30, 2025.
Promo code: ELABPQ3
No additional discounts available during this period.

Protein Tag: C-His

Uniprot: O14786-2

Accession: O14786-2

Background: Neuropilin is a type I transmembrane protein and the molecular mass is 120 kDa. Two homologs, Neuropilin-1 and Neuropilin-2, are identified. The primary structure of Neuropilin-1 and Neuropilin-2 is well conserved and is divided into four domains, CUB (a1/a2) domain, FV/FVIII (b1/b2) domain, MAM (c) domain, and (d) domain that contains a transmembrane and a short cytoplasmic region. Neuropilin-1 (NRP1) acts as a receptor for two different extracellular ligands, class 3 semaphorins, and specific isoforms of vascular endothelial growth factor. The functions of NRP1 and NRP2 have been extensively studied in neurons where they act in axon guidance and in endothelial cells where they promote angiogenesis and cell migration. Neuropilin-1 is likely to mediate contacts between the dendritic cells and the T lymphocytes via homotypic interactions and is essential for the initiation of the primary immune response. NRP1 is a co-receptor for VEGF receptor-2 (VEGFR2) that enhances the binding of VEGF165 to VEGFR2 and VEGF165-mediated chemotaxis. NRP1 expression is regulated in EC by tumor necrosis factor-alpha, the transcription factors dHAND and Ets-1, and vascular injury. NRP1 upregulation is positively correlated with an the progression of various tumors. Overexpression of NRPI in rat tumor cells results in enlarged tumors and substantially enhanced tumor angiogenesis. On the other hand, soluble NRP1 (sNRP1) is an antagonist of tumor angiogenesis.

Bio Acitivity: Not validated for activity

Sequence: Phe22-Lys644

Purity: > 90% as determined by reducing SDS-PAGE.

Formulation: Lyophilized from a 0.2 μm filtered solution in PBS with 5% Trehalose and 5% Mannitol.

Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Endotoxin: < 1.0 EU/mg of the protein as determined by the LAL method.

Calculated MW: 68.4 kDa

Observed MW: 80-90 kDa
Mehr Informationen
Artikelnummer ELSPDMH100255-500
Hersteller Elabscience Biotechnology
Hersteller Artikelnummer PDMH100255-500
Verpackungseinheit 500μg
Mengeneinheit STK
Produktinformation (PDF)
×
MSDS (PDF)
×